About us

Protecting against pneumococcal infections: Market analysis of Pneumococcal Conjugate Vaccine (PCV).

The project defines where the client can expand PCV uptake and win procurement contracts. It directs commercial investment toward vaccination programs and population groups where disease burden, funding conditions, and product differentiation create opportunities for growth.

Outcome

  • Validated growth priorities across childhood and adult vaccination, distinguishing eligible populations from demand supported by funding and practical access.
  • Clear product positioning based on relevant serotype coverage, clinical evidence, and vaccination program requirements.
  • Defined market access and procurement priorities, connecting evidence requirements and pricing with the selection factors.
  • Commercial actions to address gaps in uptake through provider engagement, vaccination access, and reliable product availability.

KEY INTELLIGENCE OBJECTIVES

  • Estimate market volume and value by vaccine, age group and funding channel, accounting for vaccination coverage, doses per schedule, and catch-up opportunities.
  • Assess disease burden and circulating pneumococcal serotypes by population group, establishing how vaccine coverage aligns with prevention needs.
  • Map vaccination recommendations, eligibility and public funding, identifying the decision processes and evidence requirements for program inclusion or product replacement.
  • Benchmark competing PCVs by approved indications, serotype coverage, clinical evidence, dosing schedules, and commercial positioning, including the role of polysaccharide vaccines in relevant vaccination pathways.
  • Examine procurement and pricing practices, including tender criteria, contract duration, purchasing volumes, and supply commitments, identifying what drives supplier selection beyond acquisition price.
  • Map vaccination delivery through pediatric services, primary care, specialist clinics, and pharmacies where permitted, identifying who recommends, purchases, and administers vaccines.
  • Identify barriers to uptake and schedule completion, including missed recommendations, limited awareness, affordability, and difficulties accessing vaccination services.
  • Assess competitor engagement strategies, distribution capabilities, and product pipelines, determining how new launches and evolving vaccination policies may reshape demand and market share.

Geography

  • Europe
  • Middle East
  • Africa
  • North America
  • Latin America
  • Asia-Pacific
  • Global

    • Go back to our case studies

    Get the report

    SUBSCRIBE TO MARKET MINDS

    What matters now. Subscribe to receive intelligence that helps you act before others do.

    Contact us

    Let’s start with a conversation.
    Tell us what you’re facing.

    EMBS GROUP Sp. z o.o. Sp. k., as the Data Administrator, will process the personal data provided above to respond to the message sent via the form. You can contact us at gdpr@embs-group.com or our registered office (Poland, 30-224 Kraków, Aleja Sosnowa 2a).
    The full text of the information clause is available in the Privacy Policy.
    Privacy Overview

    EMBS Group, as the Data Administrator, uses cookies to enhance user experience and analyze website traffic. You can change your cookie settings at any time. For more information, please see our Privacy Policy.